Autres langues Vicore Pharma Holding AB

Actions

VICO

SE0007577895

Temps Différé Nasdaq Stockholm Autres places de cotation 10:56:16 14/05/2024			Varia. 5j.	Varia. 1 janv.
21,35 ^SEK	+1,43 %		+6,48 %	+50,56 %

07/05	Vicore Pharma Holding AB (Publ) annonce des nominations au conseil d'administration	CI
03/05	Vicore Pharma Holding AB (publ) annonce ses résultats pour le premier trimestre terminé le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vicore Expands and Strengthens its Board of Directors	08:00
Vicore Pharma Holding AB Announces Board Appointments	07/05
Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)	07/05
Interim report January-March 2024	03/05
Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05
Vicore to Present at Upcoming April 2024 Investor Conferences	15/04
Vicore to Present at Upcoming Investor Conferences	15/04
Vicore to Present at Upcoming Investor Conferences	12/04
Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election	04/04
Notice of annual general meeting of Vicore Pharma Holding AB (publ)	04/04
Vicore Announces Presentations at the 2024 American Thoracic Society International Conference	28/03
Vicore publishes the Annual Report for 2023	27/03
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis	19/03
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis	19/03
Year-end report 2023	28/02
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Vicore to Present at Upcoming Investor Conferences	27/02
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	09/02
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan	09/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Vicore Pharma Holding AB

Actions

VICO

SE0007577895

Autres langues

Filtres